"10.1371_journal.pone.0087268","plos one","2014-01-31T00:00:00Z","Hanne A Askautrud; Elisabet Gjernes; Gjermund Gunnes; Marit Sletten; Douglas T Ross; Anne Lise Børresen-Dale; Nina Iversen; Michael A Tranulis; Eirik Frengen","Department of Medical Genetics, University of Oslo, Oslo, Norway; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Department of Basic Sciences and Aquatic Medicine, Norwegian School of Veterinary Science, Oslo, Norway; Clarient Diagnostic Services, Aliso Viejo, California, United States of America; Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway","Conceived and designed the experiments: HAA EG GG MAT EF. Performed the experiments: HAA EG GG MS NI MAT EF. Analyzed the data: HAA EG GG NI MAT EF. Contributed reagents/materials/analysis tools: HAA EG DTR ALBD EF. Wrote the paper: HAA EG GG MAT EF.","Douglas Ross is employed by Clarient Inc., who have developed an antibody to NDRG1 as part of a marketed product for risk stratification of breast cancer (Mammostrat). This publication does not have any impact upon this product. There are no patents, products in development or other marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.","2014","01","Hanne A Askautrud","HAA",9,TRUE,5,7,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
